Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Paul S Jones

Showing results (1-10 of 15) with videos related to

Pageof 2
Sort By:
Drug Discovery Today|December 31, 2011
New regulatory framework for cancer drug developmentPaul S Jones, David Jones
Missouri Medicine|August 1, 2025
Lower Extremity Orthotic Device Prescriptions: Basics of Evaluation and ManagementBenjamin Boyett, Paul S Jones
Bioorganic & Medicinal Chemistry Letters|May 6, 2003
Design and synthesis of spiro-cyclopentenyl and spiro-[1,3]-dithiolanyl substituted pyrrolidine-5,5-trans-lactams as inhibitors of hepatitis C virus NS3/4A proteaseDavid M Andrews, Paul S Jones, Gail Mills, et al.
Organic Letters|December 6, 2002
Pyrrolidine-5,5-trans-lactams. 1. Synthesis and incorporation into inhibitors of hepatitis C virus NS3/4A proteaseDavid M Andrews, Seb J Carey, Helene Chaignot, et al.
Mabs|December 12, 2023
Discovery of ginisortamab, a potent and novel anti-gremlin-1 antibody in clinical development for the treatment of cancerGareth C G Davies, Neesha Dedi, Paul S Jones, et al.
Organic Letters|December 6, 2002
Pyrrolidine-5,5-trans-lactams. 2. The use of X-ray crystal structure data in the optimization of P3 and P4 substituentsDavid M Andrews, Helene Chaignot, Barry A Coomber, et al.
Organic Letters|November 25, 2003
Pyrrolidine-5,5-trans-lactams. 4. Incorporation of a P3/P4 urea leads to potent intracellular inhibitors of hepatitis C virus NS3/4A proteaseMartin J Slater, Elizabeth M Amphlett, David M Andrews, et al.
European Journal of Medicinal Chemistry|May 17, 2003
The design of potent, non-peptidic inhibitors of hepatitis C proteaseDavid M Andrews, Helene M Chaignot, Barry A Coomber, et al.
Organic Letters|November 25, 2003
Pyrrolidine-5,5-trans-lactams. 5. Pharmacokinetic optimization of inhibitors of hepatitis C virus NS3/4A proteaseDavid M Andrews, Michael C Barnes, Mike D Dowle, et al.
Nature Reviews. Clinical Oncology|December 6, 2018
A framework for the development of effective anti-metastatic agentsRobin L Anderson, Theo Balasas, Juliana Callaghan, et al.
Pageof 2

Showing results (1-10 of 15) with videos related to

Sort By:
Pageof 2
Drug Discovery Today|December 31, 2011
New regulatory framework for cancer drug developmentPaul S Jones, David Jones
Missouri Medicine|August 1, 2025
Lower Extremity Orthotic Device Prescriptions: Basics of Evaluation and ManagementBenjamin Boyett, Paul S Jones
Bioorganic & Medicinal Chemistry Letters|May 6, 2003
Design and synthesis of spiro-cyclopentenyl and spiro-[1,3]-dithiolanyl substituted pyrrolidine-5,5-trans-lactams as inhibitors of hepatitis C virus NS3/4A proteaseDavid M Andrews, Paul S Jones, Gail Mills, et al.
Organic Letters|December 6, 2002
Pyrrolidine-5,5-trans-lactams. 1. Synthesis and incorporation into inhibitors of hepatitis C virus NS3/4A proteaseDavid M Andrews, Seb J Carey, Helene Chaignot, et al.
Mabs|December 12, 2023
Discovery of ginisortamab, a potent and novel anti-gremlin-1 antibody in clinical development for the treatment of cancerGareth C G Davies, Neesha Dedi, Paul S Jones, et al.
Organic Letters|December 6, 2002
Pyrrolidine-5,5-trans-lactams. 2. The use of X-ray crystal structure data in the optimization of P3 and P4 substituentsDavid M Andrews, Helene Chaignot, Barry A Coomber, et al.
Organic Letters|November 25, 2003
Pyrrolidine-5,5-trans-lactams. 4. Incorporation of a P3/P4 urea leads to potent intracellular inhibitors of hepatitis C virus NS3/4A proteaseMartin J Slater, Elizabeth M Amphlett, David M Andrews, et al.
European Journal of Medicinal Chemistry|May 17, 2003
The design of potent, non-peptidic inhibitors of hepatitis C proteaseDavid M Andrews, Helene M Chaignot, Barry A Coomber, et al.
Organic Letters|November 25, 2003
Pyrrolidine-5,5-trans-lactams. 5. Pharmacokinetic optimization of inhibitors of hepatitis C virus NS3/4A proteaseDavid M Andrews, Michael C Barnes, Mike D Dowle, et al.
Nature Reviews. Clinical Oncology|December 6, 2018
A framework for the development of effective anti-metastatic agentsRobin L Anderson, Theo Balasas, Juliana Callaghan, et al.
Pageof 2